Dr Adrian Hill
Senior Impact and Partnership Development Manager - Healthcare and Biotechnology
Innovation Centre, University of Exeter, Rennes Drive, Exeter, EX4 4RN, UK
Adrian is the Innovation, Impact and Business (IIB) lead for the Living Systems Institute (LSI) and the Healthcare and Biotech theme. His team is tasked with supporting theme-related impact development, collaboration with external partners and income generation across the University.
He is the main point of contact for many of the leading pharmaceutical and biotechnology companies.
Dr Adrian Hill has a background in developmental neurotoxicology obtained through doctoral and postdoctoral positions at the University of Liverpool, the Institut de Génétique et de Biologie Moléculaire et Cellulaire and the University of Wisconsin-Madison, and obtained a further qualification in Business and Administration from Liverpool.
For many years he was actively involved in the toxicology conference circuit and during his career has published a number of associated research articles and book chapters, acted as a reviewer for prominent scientific journals and the EU commission, and has been a guest speaker at numerous international meetings and the FDA.
He joined VASTox plc as a principal scientist in 2005 tasked with developing new and alternative models for screening drug toxicity, safety and efficacy, and in 2006 became Head of Toxicology at Summit plc, an SME acting as a contract research service provider as well as a drug discovery company focused primarily on musculoskeletal disorders. From 2009 Adrian led ADMET teams in the UK and Singapore as Associate Director at Evotec AG, a leading CRO, and was also a Business Development Manager tasked with selling niche services to the pharmaceutical and agrochemical community over a global territory.
From 2012 Adrian worked for the University of Nottingham as a Senior Executive in Corporate Partnerships representing the pharmaceuticals, biotechnology and healthcare sector and in 2014 became a Board Director for Exonate, an SME spin-out focused on ophthalmic and oncology-related drug discovery. Adrian joined the University of Exeter in May 2016.